A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence

Table 3 38G model performance compared to CAPRA-S for association with BCR in the validation cohort (n = 423)

	Sensitivity	Specificity	PPV	NPV
Overall BCR
38G	81.4	36.33	15.02	93.39
CAPRA-S	52.5	72.67	20.39	91.98
BCR within 1.5 years
38G	77.78	35.17	9.01	95.04
CAPRA-S	52	71.43	12.62	94.94
BCR within 3 years
38G	81.58	36.08	13.3	89.27
CAPRA-S	51.43	72.13	17.48	92.83
BCR within 5 years
38G	80.95	36.22	14.59	93.39
CAPRA-S	53.85	72.76	20.39	92.41
BCR within 7 years
38G	81.4	36.33	15.02	93.39
CAPRA-S	52.5	72.67	20.39	91.98

ISSN: 1471-2407